7 completed, 1 withdrawn. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Interleukin-18: new trials by email Literature Review of Interleukin-18 trials Research Report on Interleukin-18
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Host Dysregulation-Driven Sepsis Prediction Model Tumor Necrosis Factor, Interleukin-1β, Interleukin-12 - Sepsis | Completed | Second Affiliated Hospital of Wenzhou Medical University | 1000 | 2024-09-01 | 2024-10-31 | |
| A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells, SB---485232 (Human recombinant Interleukin---18) - Ovarian, Fallopian Tube and Peritoneal Cancer | Phase 1 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2014-09-01 | 2018-09-27 | |
| Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma Ofatumumab combined with SB-485232 - Non-Hodgkin's Lymphoma | Phase 1 | Completed | Michael John Robertson | 9 | 2013-02-01 | 2023-02-10 |
| Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer SB-485232 (interleukin 18), pegylated liposomal doxorubicin - Neoplasms, Ovarian | Phase 1 | Completed | GlaxoSmithKline | 15 | 2008-06-18 | 2017-07-21 |
| A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 SB-485232, Rituximab - Lymphoma, Non-Hodgkin | Phase 1 | Completed | GlaxoSmithKline | 24 | 2007-07-31 | 2017-07-26 |
| Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma SB-485232 - Melanoma | Phase 2 | Completed | GlaxoSmithKline | 64 | 2004-11-15 | 2017-07-27 |
| Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas SB-485232 - Solid Tumor Cancer, Lymphoma | Phase 1 | Completed | GlaxoSmithKline | 12 | 2004-04-01 | 2008-10-13 |
| Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors SB-485232 - Solid Tumor Cancer | Phase 1 | Completed | GlaxoSmithKline | 25 | 2003-01-01 | 2008-10-16 |
Lymphoma, Non-Hodgkin (2) · Neoplasms (2) · Lymphoma (1) · Melanoma (1) · Ovarian Neoplasms (1) · Sepsis (1)
GlaxoSmithKline (5) · Abramson Cancer Center at Penn Medicine (1) · Michael John Robertson (1) · Second Affiliated Hospital of Wenzhou Medical University (1)
United States (7) · Australia (1) · China (1)